Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 Jul;26(7):1417-1421.
doi: 10.1111/1756-185X.14752. Epub 2023 May 23.

A patient with refractory proliferative lupus nephritis treated with telitacicept: A case report

Jing-Wen Chen  1   2 , Jing-Yi Zhan  1   2 , Si-Ping Liang  1   2 , Xiao-Dan Wang  3 , Chang-Song Lin  1   2 , Qiang Xu  1   2
Affiliations
Case Reports

A patient with refractory proliferative lupus nephritis treated with telitacicept: A case report

Jing-Wen Chen et al. Int J Rheum Dis. 2023 Jul.

Abstract

Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease. Lupus nephritis (LN) is a common type of organ damage which occurs in SLE patients and is characterized by recurrent proteinuria. Activation of B lymphocytes can lead to refractory LN, which is an important pathogenic factor in SLE. B lymphocyte stimulator (BLyS) and A proliferation-inducing ligand (APRIL) are predominantly produced by myeloid cells (monocytes, dendritic cells, neutrophils, etc) to regulate B lymphocyte function. Telitacicept was the first dual-targeting biological drug which targeted both BLyS and APRIL. Telitacicept has passed a phase II clinical trial and has since been approved for the treatment of SLE.

Case presentation: We report a case of SLE confirmed by renal biopsy as proliferative lupus nephritis (PLN) with massive proteinuria, which was treated with telitacicept (European League Against Rheumatism / American College of Rheumatology 2019 standard). During the 19 months of follow-up, the patient's renal function was stable, massive proteinuria was relieved, and creatinine and blood pressure did not increase.

Conclusions: During the 19 months of telitacicept treatment (160 mg once weekly), PLN reduced blood system damage and proteinuria without increasing the risk of infection.

Keywords: APRIL; B-cell lymphocyte stimulator; proliferative lupus nephritis; systemic lupus erythematosus; telitacicept.

PubMed Disclaimer

References

REFERENCES

    1. Hahn BH. Targeted therapies in systemic lupus erythematosus: successes, failures and future. Ann Rheum Dis. 2011;70(Suppl 1):i64-i66. doi:10.1136/ard.2010.142208
    1. Yokoyama H, Wada T, Furuichi K. Chemokines in renal fibrosis. Contrib Nephrol. 2003;139:66-89. doi:10.1136/ard.2010.142208
    1. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Working Group. KDIGO 2021 clinical practice guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. doi:10.1016/j.kint.2021.05.021
    1. Pons-Estel GJ, Serrano R, Plasin MA, Espinosa G, Cervera R. Epidemiology and management of refractory lupus nephritis. Autoimmun Rev. 2011;10(11):655-663. doi:10.1016/j.autrev.2011.04.032
    1. Das U, Patel R, Guditi S, Taduri G. Correlation between the clinical remission and histological remission in repeat biopsy findings of quiescent proliferative lupus nephritis. Lupus. 2021;30(6):876-883. doi:10.1177/0961203321995251

Publication types

LinkOut - more resources